Filter By Category
Archives
Share on -
ANETUMAB RAVTANSINE
Generic Name: ANETUMAB RAVTANSINE
ABSTRACT -
Anetumab ravtansine is an investigational mesothelin-directed antibody-drug conjugate. It contains a fully human anti-mesothelin IgG1 antibody conjugated through a reducible linker to the maytansinoid DM4 payload, which disrupts microtubule dynamics after internalization by mesothelin-expressing tumor cells.
DOSAGE -
- Dosage should be determined only by a qualified oncology specialist.
- No approved standard dose is established for general use.
- Clinical studies used intravenous dosing on protocol-defined schedules, often every three weeks.
- Monitor blood counts, liver tests, neurologic symptoms, and ocular findings according to protocol.
SIDE EFFECTS–
- Possible side effects include:
- Fatigue
- Nausea
- Peripheral neuropathy
- Ocular toxicity or blurred vision
- Reduced appetite
- Diarrhea or constipation
- Liver enzyme abnormalities
- Cytopenias
- Infusion-related reactions
ALLRGIC REACTIONS–
- Possible allergic reaction symptoms include:
- Rash
- Urticaria
- Facial swelling
- Bronchospasm
- Anaphylaxis symptoms
- Important: Patients who develop an allergic reaction to Anetumab Ravtansine should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS–
- Other neurotoxic or myelosuppressive anticancer drugs may increase toxicity.
- Strong CYP3A modulators could alter exposure to maytansinoid-related payloads.
- Live vaccines should be avoided during clinically significant immunosuppression.
- Concomitant ocular-toxic agents require caution.
- Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Use only within oncology protocols or authorized programs.
- Confirm mesothelin expression when required.
- Monitor for neuropathy, ocular toxicity, hepatotoxicity, and cytopenias.
- Use contraception during and after treatment according to protocol.
WARNINGS –
- Investigational ADC; not for routine self-use.
- Severe infusion reactions, ocular toxicity, neuropathy, or marrow suppression require urgent assessment.
- May cause fetal harm.
- Keep out of reach of children.
Share on -
. Developed by